NCT04747912 2026-03-30
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
University of Chicago
Phase 2 Suspended
University of Chicago
University of Texas Southwestern Medical Center
Cyclacel Pharmaceuticals, Inc.
Shanghai Jiao Tong University School of Medicine
Humanigen, Inc.
Nordic Society for Pediatric Hematology and Oncology
MedImmune LLC